UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 150

Sortiert nach

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

The New England journal of medicine, 2011-06, Vol.364 (26), p.2507-2516

2011

Volltextzugriff (PDF)

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

Journal of clinical oncology, 2013-09, Vol.31 (26), p.3205-3211

2013

Volltextzugriff (PDF)

Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D

Cancer research (Chicago, Ill.), 2012-01, Vol.72 (2), p.460-471

2012

Volltextzugriff (PDF)

Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease

European journal of cancer (1990), 2014-03, Vol.50 (4), p.774-783

2014

Volltextzugriff (PDF)

RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors

Journal of clinical oncology, 2012-01, Vol.30 (3), p.316-321

2012

Volltextzugriff (PDF)

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

International journal of cancer, 2013-10, Vol.133 (7), p.1653-1663

2013

Volltextzugriff (PDF)

Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

Journal of clinical oncology, 2012-11, Vol.30 (31), p.3810-3818

2012

Volltextzugriff (PDF)

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

Journal of clinical oncology, 2009-06, Vol.27 (17), p.2823-2830

2009

Volltextzugriff (PDF)

Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition

Journal of clinical oncology, 2012-07, Vol.30 (19), p.2375-2383

2012

Volltextzugriff (PDF)

Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma

Clinical cancer research, 2009-02, Vol.15 (4), p.1384-1392

2009

Volltextzugriff (PDF)

Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling

Journal of clinical oncology, 2009-05, Vol.27 (13), p.2199-2208

2009

Volltextzugriff (PDF)

Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B

Clinical cancer research, 2009-08, Vol.15 (16), p.5208-5215

2009

Volltextzugriff (PDF)

Endosialin (Tem1) Is a Marker of Tumor-Associated Myofibroblasts and Tumor Vessel-Associated Mural Cells

The American journal of pathology, 2008-02, Vol.172 (2), p.486-494

2008

Volltextzugriff (PDF)

Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis

Journal of clinical oncology, 2012-05, Vol.30 (15), p.1835-1841

2012

Volltextzugriff (PDF)

Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth

Cancer research (Chicago, Ill.), 2009-02, Vol.69 (4), p.1324-1333

2009

Volltextzugriff (PDF)

A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up

European journal of cancer (1990), 2011-09, Vol.47 (13), p.1977-1989

2011

Volltextzugriff (PDF)

Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group

Journal of clinical oncology, 2009-06, Vol.27 (18), p.2916-2923

2009

Volltextzugriff (PDF)

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

Clinical cancer research, 2008-02, Vol.14 (3), p.856-864

2008

Volltextzugriff (PDF)

Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

Journal of clinical oncology, 2005-09, Vol.23 (27), p.6747-6755

2005

Volltextzugriff (PDF)

Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines

Carcinogenesis (New York), 2005-07, Vol.26 (7), p.1224-1232

2005

Volltextzugriff (PDF)

Efficacy of Low-Dose Interferon α2a 18 Versus 60 Months of Treatment in Patients With Primary Melanoma of ≥ 1.5 mm Tumor Thickness: Results of a Randomized Phase III DeCOG Trial

Journal of clinical oncology, 2010-02, Vol.28 (5), p.841-846

2010

Volltextzugriff (PDF)

The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma Cells

Journal of investigative dermatology, 2011-02, Vol.131 (2), p.468-479

2011

Volltextzugriff (PDF)

Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma Patients

Journal of clinical oncology, 2005-08, Vol.23 (22), p.5088-5093

2005

Volltextzugriff (PDF)

Tumor type M2 pyruvate kinase (TuM2‐PK) as a novel plasma tumor marker in melanoma

International journal of cancer, 2005-12, Vol.117 (5), p.825-830

2005

Volltextzugriff (PDF)

Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group

Journal of clinical oncology, 2005-12, Vol.23 (35), p.9001-9007

2005

Volltextzugriff (PDF)

1 – 25 von 150

Suche als RSS-Feed

Aktive Filter

ThemaMedical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(145)
Mit Volltextzugriff
(137)

Publikationsform

Artikel
(149)
Tagungsberichte
(1)

Sprache

Englisch
(150)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(150)
Humans
(132)
Science & Technology
(131)
Life Sciences & Biomedicine
(130)
Dermatology
(91)
Oncology
(83)
Tumors Of The Skin And Soft Tissue. Premalignant Lesions
(77)
Female
(65)
Pharmacology. Drug Treatments
(63)
Male
(61)
Tumors
(58)
Middle Aged
(56)
Antineoplastic Agents
(55)
Aged
(44)
Adult
(43)
Melanoma
(38)
Melanoma - Pathology
(37)
Skin Neoplasms - Pathology
(30)
Immunotherapy
(28)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D

Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease

RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition

Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma

Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling

Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B

Endosialin (Tem1) Is a Marker of Tumor-Associated Myofibroblasts and Tumor Vessel-Associated Mural Cells

Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis

Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth

A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up

Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines

Efficacy of Low-Dose Interferon α2a 18 Versus 60 Months of Treatment in Patients With Primary Melanoma of ≥ 1.5 mm Tumor Thickness: Results of a Randomized Phase III DeCOG Trial

The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma Cells

Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma Patients

Tumor type M2 pyruvate kinase (TuM2‐PK) as a novel plasma tumor marker in melanoma

Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group

Aktive Filter

Suchergebnisse filtern